维多珠单抗相关附着点炎在成功治疗的IBD患者中的患病率与真实世界管理
一项意大利单中心队列研究纳入90例接受维多珠单抗(VDZ)治疗的IBD患者,其中11例出现新发严重附着点炎(占8%),多数HLA-B27阴性且肠道反应良好。所有患者初始接受NSAIDs,部分局部激素注射;12个月随访时多数继续VDZ,部分换用乌司奴单抗,部分达到临床缓解。
要点
- VDZ治疗IBD患者中约8%出现新发严重附着点炎,多为孤立附着点炎模式。
- 多数患者HLA-B27阴性且肠道疾病控制良好,超声可见附着点严重病变及能量多普勒信号。
- 多数患者继续VDZ治疗,12个月时部分达到临床缓解,部分出现附着点钙化。
核心结论
- 维多珠单抗治疗IBD过程中可能以孤立严重附着点炎模式诱发脊柱关节炎,在成功治疗的患者中约占8%。
研究设计与样本
- 意大利单中心IBD单元队列研究,90例接受维多珠单抗治疗的患者中识别11例新发严重附着点炎。
主要发现
- 11例中8例既往抗TNF失败,表现为多灶性(4例)、单灶性(6例)及附着点炎/滑膜炎/指趾炎(1例)。
- 症状平均持续46周(范围6-119周),平均CRP为5.1 mg/dl,多数HLA-B27阴性且肠道反应良好。
- 超声显示严重附着点炎,7例出现能量多普勒信号改变。
- 12个月随访7例中,5例继续VDZ,2例换用乌司奴单抗;5例临床缓解,2例轻度附着点炎伴能量多普勒信号轻微增加。
- 7例严重患者中4例出现明显的炎症后附着点钙化。
关键数值与推荐
- 原文未报告诊断标准或治疗推荐条款。
临床怎么用
- 接受维多珠单抗治疗的IBD患者出现新发关节/附着点症状时,应警惕药物相关脊柱关节炎,即使肠道疾病控制良好。
局限性
- 单中心小样本病例系列,缺乏对照,无法确定因果关系或患病率精确估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some studies have reported the development of moderate and severe de novo SpA-associated disease under vedolizumab (VDZ) treatment for IBD. Herein, we report a case series who developed severe enthesitis under VDZ therapy from a cohort of 90 treated cases. METHODS: In a single Italian IBD Unit in which 90 cases were on VDZ therapy, we identified 11 cases who developed severe enthesitis. The onset of disease in relationship to VDZ initiation, clinical and sonographic imaging features, and outcomes (including therapy switches) was described. RESULTS: A total of 11 cases, including 8 prior anti-TNF failures, with new-onset entheseal pathology were identified: multifocal (n = 4), unifocal (n = 6), and enthesitis/synovitis/dactylitis (n = 1). The mean duration of symptoms was 46 weeks (range 6-119), the mean CRP was 5.1 mg/dl, and the majority were HLA-B27 negative and showed good clinical response for gut disease. Clinical features and US showed severe enthesitis, including power Doppler change in 7 patients. All patients were initially treated with NSAIDs, and 5 patients underwent local steroid injections. At 12 months, 5/7 cases continued VDZ and 2 were switched to ustekinumab. At 12 months follow-up of 7 cases, 5 patients were in clinical remission and 2 patients had mild enthesitis with minimal increase of power Doppler signal. In addition, 4/7 severe patients developed marked post-inflammatory entheseal calcifications. CONCLUSIONS: A predominant isolated severe enthesitis pattern of SpA may develop under VDZ therapy with severe disease in 8% of cases. Most cases continued VDZ therapy.
引用
- Ruscio MD, Tinazzi I, Variola A, et al. Prevalence and real-world management of vedolizumab-associated enthesitis in successfully treated IBD patients. Rheumatology (Oxford). 2021. PMID: 33580246. doi:10.1093/rheumatology/keab135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。